Video Highlights
1:31 Priya Nori, MD
4:21 Cornelius Clancy, MD
7:10 Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP
|Videos|November 21, 2021
Antibiotic Prescribing Practices During COVID-19
Author(s)John Parkinson
As providers were challenged to care for patients with severe COVID-19 In the first year of the pandemic, antibiotic usage increased. Listen to clinicians talk about this specific challenge and how prescribing practices evolved over time.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: One of the things that is being reported is that during the first year of the pandemic antibiotics were over prescribed. Do you agree with that assessment and do you think we are seeing a return to normal prescribing practices now?
We interviewed Priya Nori, MD, director, Antibiotic Stewardship, Montefiore Health System, Cornelius (Neil) Clancy, MD, associate professor of Medicine and director of the Mycology Program at the University of Pittsburgh, and Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP assistant professor of Pharmacy Practice at Loma Linda University School of Pharmacy.
Check out our video to hear their insights.
Advertisement
Related to this article
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Adding bismuth to amoxicillin-vonoprazan increased efficacy of the combination for H pylori, and exceeded that of clarithromycin-based triple therapy without contributing to clarithromycin resistance.
Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
Vibrio species are bacteria that live in saltwater environments. When ingested orally or through contact with open wounds, some species can cause severe life-threatening infections, particularly in those with high-risk conditions, such as liver disease. Here is a review of Vibrio vulnificus and the recommended antibiotic treatment.
Advertisement
Advertisement
Trending on Contagion Live
1
A Pennsylvania Teen Dies From Rare Measles Neurological Complication
2
Revisiting Whether Cefepime Raises Mortality Risk
3
New York City Orders Tower Cleanings, Announces Prevention Measures in Addressing Legionnaires' Disease Cluster
4
Ceftriaxone Safety: Separating Signal From Risk
5